Reports Q1 revenue $1.036B, consensus $1.02B. “To start the year, Dexcom (DXCM) delivered a quarter of strong revenue results and unlocked significant new type 2 coverage,” said Kevin Sayer, Dexcom’s chairman, president and CEO. “As we progress through 2025, we will advance our product portfolio with the launch of our Dexcom G7 15 Day system and continue to advocate for expanded global access to our glucose biosensors.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM: